CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sai Parenteral's Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sai Parenteral's Ltd
No-39, Lavanya Arcade,, 4Th Floor
Phone: +91 7997991301p:+91 7997991301 HYDERABAD, 500032  India Ticker: SAIPARENTSAIPARENT
Business Summary
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20253/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2869 Industrial organic chemicals, not elsewhere classified
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, Managing Director Anil K.Karusala 52 8/26/2025 11/19/2021
Chief Executive Officer D.B.VenkojiPrakash 8/26/2025 8/26/2025
Chief Financial Officer AnilKumar 9/11/2025 9/11/2025
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 298 (As of 12/31/2025)
Outstanding Shares: 44,179,231 (As of 9/30/2025)
Stock Exchange: NSE


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 11, 2026